Journal of Cancer Therapy

Vol.7 No.8(2016), Paper ID 69837, 8 pages

DOI:10.4236/jct.2016.78062

 

The Use of PSA Doubling Time to Predict Prognosis and the Use of PSA Response to Assess the Success for Prostate Cancer Patients Undergoing Docetaxel Chemotherapy

 

Sarp K. Keskin, Asif Yildirim, Cengiz Canakci, Ismail Ulus, Ramazan Gokhan Atis, Turhan Caskurlu

 

Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, USA
Department of Urology, The University of Istanbul Medeniyet, Goztepe Training and Research Hospital, Istanbul, Turkey
Department of Urology, The University of Istanbul Medeniyet, Goztepe Training and Research Hospital, Istanbul, Turkey
Department of Urology, The University of Istanbul Medeniyet, Goztepe Training and Research Hospital, Istanbul, Turkey
Department of Urology, The University of Istanbul Medeniyet, Goztepe Training and Research Hospital, Istanbul, Turkey
Department of Urology, The University of Istanbul Medeniyet, Goztepe Training and Research Hospital, Istanbul, Turkey

 

Copyright © 2016 Sarp K. Keskin, Asif Yildirim, Cengiz Canakci, Ismail Ulus, Ramazan Gokhan Atis, Turhan Caskurlu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

 

How to Cite this Article


Keskin, S. , Yildirim, A. , Canakci, C. , Ulus, I. , Atis, R. and Caskurlu, T. (2016) The Use of PSA Doubling Time to Predict Prognosis and the Use of PSA Response to Assess the Success for Prostate Cancer Patients Undergoing Docetaxel Chemotherapy. Journal of Cancer Therapy, 7, 593-599. doi: 10.4236/jct.2016.78062.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.